A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia

• Status: Terminated
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to evaluate if DVS SR is safe and effective in the treatment of pain associated with fibromyalgia syndrome, and if so to identify the efficacious doses.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Desvenlafaxine Succinate; Pregabalin

Criteria

Inclusion Criteria:

• Fibromyalgia diagnosed according to 1990 American College of Rheumatology criteria

Exclusion Criteria:

• Unstable medical or psychological conditions that would compromise the subject's safety or put the subject at greater risk during study participation

• Other painful conditions that may confound the diagnosis or assessment of fibromyalgia

• Treatment with other drugs for fibromyalgia with 14 days of study start or during the study